Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit - DXCM

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud related to the company's glucose monitoring products, specifically the G6 and G7 models, during the period from July 26, 2024, to September 17, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [2]. - It is alleged that these design changes compromised the reliability of the G6 and G7 devices, posing a significant health risk to users who depend on accurate glucose readings [2]. - The complaint asserts that the enhancements claimed for the G7 device, including its reliability and accuracy, were overstated by the defendants [2]. - The lawsuit also contends that the true extent of the issues and health risks associated with the G7 devices was downplayed by the defendants [2]. - As a result of these actions, DexCom faced increased risks of regulatory scrutiny and potential legal, reputational, and financial harm [2]. - The public statements made by the defendants were characterized as materially false and misleading throughout the relevant time period [2]. Group 2: Legal Process and Participation - Investors who suffered losses in DexCom, Inc. during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require individuals to serve as lead plaintiffs to be eligible for potential compensation [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]. - The firm has extensive experience in complex securities litigation, supported by a team of over 70 employees [4].